Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures
The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working in this area with almost no success for decades, yet still feels a commitment to keep trying, Lilly Research Labs President Daniel Skovronsky tells Scrip.
You may also be interested in...
The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.